Australian Pregnancy Register Please call us: 1800 069 722
Australian Pregnancy Register for Women on Antiepileptic Medication with Epilepsy and Allied Conditions
ABN: 38 128 668 797
This is a voluntary, nationwide study that is enrolling women who are currently pregnant or who have given birth recently (infants up to 12 months of age) in the following categories:
Women with epilepsy taking antiepileptic medication (AEDs).
Women with epilepsy not taking AEDs.
Women taking AEDs for allied conditions.
The program needs a significant boost to the number of women participating in the study, as well as increasing the length of the study, to ensure enough evidence is collected for the findings to become treatment guidelines.
From previous research it is known that women who are taking an AED may have a slightly higher incidence (4-6%) of having babies with birth defects than the general population (2-3%).
The Australian Pregnancy Register (APR) is an independent project that has been running for over 16 years nationally. We are an observational register and collect information about pregnant women with epilepsy, treated and untreated, to determine which AEDs are safest for the baby while protecting the mother from seizures.
Information from pregnancy registers is a valuable resource for the
study of comparative risks and benefits of antiepileptic drugs in
pregnancy. As a result of this study we are getting closer to defining safer treatment choices.
Epilepsy Action Australia recently formed a major partnership with the Australian Pregnancy Register to enable the research to continue and increase the number of women registered. The aim is to increase the number from 2,500 to 5,000 women in 3 years.
Sam Berkovic, Andrew Bleasel, John Dunne, Wendyl D'Souza, Mervyn Eadie, Geoff Herkes, Michelle Kiley, Raphael Kuhn, Patrick Kwan, Dan McLaughlin, Jim Pelekanos, Piero Peruca, Ernie Somerville and Liz Walker
Major Financial Supporter Epilepsy Action Australia
Epilepsy Australia Epilepsy Society of Australia Eisai Janssen Cilag NHMRC Novartis RMH Neuroscience Foundation Sanofi Aventis SciGen UCB Pharma